Table 2.
Comparison of demographic and clinical features according to different SARS-CoV-2 vaccine categories
| No., % | mRNA vaccines 35, 70% | Non-mRNA vaccines | p-value* | ||
|---|---|---|---|---|---|
| Viral vector vaccinesa 9, 18% |
Inactivated virus 6, 12% |
||||
| Sex F (No., %) | 25, 71.4% | 8, 88.9% | 5, 83.3% | 0.248 | |
| Age (median, IQR) | 40.0, 34–44 | 47, 39–55 | 36, 34–38 | 0.473 | |
| European (No., %) | 19, 54.3% | 5, 55.6% | 0 | 0.019 | |
| North American (No., %) | 7, 20% | 0 | 0 | ||
| Asian (No., %) | 8, 22.9% | 4, 44.4% | 6, 100% | ||
| Australian (No., %) | 1, 2.9% | 0 | 0 | ||
| After 1st dose (No., %) | 20, 57% | 8, 88.9% | 2, 33.3% | 0.701 | |
| After 2nd dose (No., %) | 14, 40% | 1, 11.1% | 4, 66.7% | ||
| After 3rd dose (No., %) | 1, 3% | 0 | 0 | ||
| Onset (days after vaccine shot—median, IQR) | 9, 4–14 | 14, 10–14 | 7, 4–14 | 0.549 | |
| Neck pain (No., %) | 26, 74.3% | 8, 88.9% | 6, 100% | 0.123 | |
| Palpitations (No., %) | 24, 68.6% | 4, 44.4% | 4, 66.7% | 0.304 | |
| Fatigue (No., %) | 13, 37.1% | 2, 22.2% | 4, 66.7% | 0.849 | |
| Fever (No., %) | 9, 25.7% | 2, 22.2% | 2, 33.3% | 0.944 | |
| Weight loss (No., %) | 4, 11.4% | 2, 22.2% | 4, 66.7% | 0.021 | |
| Anxiety (No., %) | 6, 17.1% | 2, 22.2% | 0 | 0.736 | |
| Baseline TSH suppression (No., %) | 32, 91.3% | 8, 88.9% | 4, 66.7% | 0.254 | |
| Baseline T4 increase | |||||
| (No., %) | 26, 74.3% | 8, 88.9% | 3, 50% | 0.944 | |
| (median fold change over ULN, IQR) | 1.6, 1.4–1.9 | 1.3, 1.2–3.3 | 1.8, 1.7–2.7 | 0.971 | |
| Baseline T3 increase | |||||
| (No., %) | 12, 54.5% | 3, 60% | 4, 66.7% | 0.618 | |
| (median fold change over ULN, IQR) | 1.5, 1.3–2.1 | 1.4, 1.1–2.7 | 1.9, 1.6–2.6 | 0.499 | |
| TPOAb | 7, 21.2% | 1, 12.5% | 0 | 0.276 | |
| TgAb | 8, 28.6% | 2, 40% | 0 | 0.597 | |
| Baseline CRP increase | |||||
| (No., %) | 19, 90.5% | 5, 83.3% | 4, 66.7% | 0.233 | |
| (median fold change over ULN, IQR) | 8.4, 4.6–18.4 | 5.8, 5.7–6.9 | 10.9, 6.0–15.5 | 0.699 | |
| Baseline ESR increase | |||||
| (No., %) | 19, 90.5% | 5, 83.3%% | 5, 83.3% | 0.545 | |
| (median fold change over ULN, IQR) | 3.1, 2.2–4.4 | 2.8, 1.9–3.2 | 3.9, 2.7–6.7 | 0.885 | |
*p-value assessed by Wilcoxon rank-sum test (for continuous variables) or chi-squared test (for categorical variables), comparing mRNA vs. non-mRNA vaccines. aEvery patient in this category received Vaxzevria ChAdOx1, no cases of SAT following Janssen Ad26.COV2.S vaccine were reported